Acumen Pharmaceuticals, Inc. (ABOS) Dividend History

Acumen Pharmaceuticals, Inc. (ABOS) is a biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. The company emphasizes innovative approaches to address the underlying causes of cognitive decline, aiming to improve patient outcomes through its research and development efforts in the neurodegeneration space.

427 Park St., Charlottesville, VA, 22902
Phone: 925-368-8508
Website: https://www.acumenpharm.com

Dividend History

Acumen Pharmaceuticals, Inc. currently does not pay dividends

Company News

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it will report its first-quarter 2025 financial results on May 13, 2025.

GlobeNewswire Inc.
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results and provided an update on its Phase 2 ALTITUDE-AD trial for its Alzheimer's disease treatment candidate, sabirnetug (ACU193).

GlobeNewswire Inc.
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Acumen Pharmaceuticals presented results from its Phase 2 ALTITUDE-AD trial of sabirnetug, a potential treatment for Alzheimer's disease, and shared preclinical research methods at recent conferences. The company also published biomarker results from its Phase 1 INTERCEPT-AD trial.

GlobeNewswire Inc.
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report

The chlorinated isopropane market is expected to grow at a CAGR of 4.9% from 2025 to 2035, driven by increasing demand from the pharmaceutical and agrochemical industries. The market is projected to reach $496 million by 2035.

GlobeNewswire Inc.

Featured Companies: CDXC
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting

Acumen Pharmaceuticals will present data on the use of a plasma pTau217 assay in the screening process for its Phase 2 ALTITUDE-AD study of sabirnetug, a potential treatment for early Alzheimer's disease.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:17:38 UTC